AU2018238102B2 - Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators - Google Patents
Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators Download PDFInfo
- Publication number
- AU2018238102B2 AU2018238102B2 AU2018238102A AU2018238102A AU2018238102B2 AU 2018238102 B2 AU2018238102 B2 AU 2018238102B2 AU 2018238102 A AU2018238102 A AU 2018238102A AU 2018238102 A AU2018238102 A AU 2018238102A AU 2018238102 B2 AU2018238102 B2 AU 2018238102B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- mmol
- alkyl
- tetrahydroisoquinolin
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| GB1704714.3 | 2017-03-24 | ||
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2018238102A1 AU2018238102A1 (en) | 2019-10-31 |
| AU2018238102A2 AU2018238102A2 (en) | 2019-11-07 |
| AU2018238102B2 true AU2018238102B2 (en) | 2021-11-04 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018238102A Active AU2018238102B2 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (enExample) |
| EP (1) | EP3601229B1 (enExample) |
| JP (1) | JP7099672B2 (enExample) |
| KR (1) | KR102636166B1 (enExample) |
| CN (1) | CN110891938B (enExample) |
| AU (1) | AU2018238102B2 (enExample) |
| BR (1) | BR112019019868A2 (enExample) |
| CA (1) | CA3057415A1 (enExample) |
| GB (1) | GB201704714D0 (enExample) |
| MX (1) | MX394818B (enExample) |
| WO (1) | WO2018172727A1 (enExample) |
| ZA (1) | ZA201906873B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118084940A (zh) | 2018-02-13 | 2024-05-28 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| AU2019255750B2 (en) | 2018-04-19 | 2021-10-21 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | Gpr119 agonists |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| EP4225738A1 (en) * | 2020-10-08 | 2023-08-16 | Eli Lilly and Company | 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) * | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| WO2016105118A2 (ko) * | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| MX2008002207A (es) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 10. |
| RU2008135126A (ru) | 2006-01-30 | 2010-03-10 | Айрм Ллк (Bm) | Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar |
| EP2121675A1 (en) * | 2007-02-22 | 2009-11-25 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
| US20110065739A1 (en) | 2008-06-02 | 2011-03-17 | Makoto Ishikawa | Novel isoxazole drivative |
| US20140315881A1 (en) | 2011-07-29 | 2014-10-23 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh active Active
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) * | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| WO2016105118A2 (ko) * | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3057415A1 (en) | 2018-09-27 |
| RU2019133659A (ru) | 2021-04-26 |
| MX2019011314A (es) | 2020-01-27 |
| WO2018172727A1 (en) | 2018-09-27 |
| KR20190140936A (ko) | 2019-12-20 |
| CN110891938B (zh) | 2023-10-31 |
| JP7099672B2 (ja) | 2022-07-12 |
| CN110891938A (zh) | 2020-03-17 |
| AU2018238102A2 (en) | 2019-11-07 |
| JP2020515636A (ja) | 2020-05-28 |
| EP3601229A1 (en) | 2020-02-05 |
| AU2018238102A1 (en) | 2019-10-31 |
| GB201704714D0 (en) | 2017-05-10 |
| EP3601229B1 (en) | 2024-11-06 |
| MX394818B (es) | 2025-03-24 |
| KR102636166B1 (ko) | 2024-02-13 |
| RU2019133659A3 (enExample) | 2021-07-16 |
| US20200317619A1 (en) | 2020-10-08 |
| ZA201906873B (en) | 2022-03-30 |
| BR112019019868A2 (pt) | 2020-04-22 |
| US11220483B2 (en) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018238102B2 (en) | Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators | |
| JP2022547716A (ja) | 二機能性分解誘導薬及びそれらの使用方法 | |
| AU2012358359A1 (en) | Non-systemic TGR5 agonists | |
| AU2013344602A1 (en) | Dihydropyrazole GPR40 modulators | |
| EA030410B1 (ru) | Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
| EA030561B1 (ru) | Тетразолон-замещенные дигидропиридиноновые ингибиторы mgat2 | |
| JP2025538389A (ja) | グルカゴン様ペプチド１受容体アゴニスト | |
| WO2012173174A1 (ja) | アザスピロアルカン化合物 | |
| KR20210125471A (ko) | Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 | |
| KR20210022646A (ko) | 시아노트리아졸 화합물 및 이의 용도 | |
| JP2011506551A (ja) | Ａｍｐａ受容体増強化合物および医薬におけるその使用 | |
| JP2024504352A (ja) | ソルチリン活性のモジュレーターとしてのピリジン誘導体 | |
| WO2025021048A1 (zh) | 一类多环化合物及其用途 | |
| TW201625545A (zh) | 取代唑化合物及糖尿病治療藥 | |
| RU2776801C2 (ru) | Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120 | |
| JP7716980B2 (ja) | エストロゲン受容体拮抗剤 | |
| JP2014118368A (ja) | アザスピロアルカン化合物を有効成分として含有する血糖低下作用薬 | |
| WO2013004617A1 (en) | Pyrazolopyridines useful in the treatment of disorders of the central nervous system | |
| CN111343978A (zh) | 新型盐 | |
| JP2025535127A (ja) | 新規化合物、その製造方法および医薬品としての使用 | |
| CN118546109A (zh) | 含氮杂环类化合物及其医药用途 | |
| JP5975122B2 (ja) | ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法 | |
| EP4551560A1 (en) | Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor | |
| HK40085749A (en) | P2x3 modulators | |
| HK40061670A (en) | Compounds and compositions for treating conditions associated with apj receptor activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 OCT 2019 |
|
| FGA | Letters patent sealed or granted (standard patent) |